PURPOSE: This study evaluates the potential of serum pro-inflammatory cytokines as AMD biomarkers. METHODS: Serum samples from 30 age-related macular degeneration (AMD) patients and 15 age-matched controls were examined for 16 inflammatory cytokines using multiplex ELISA. Patients were divided into three subgroups (improvement/no change/deterioration during anti-VEGF treatment) by OCT and funduscopy, and correlated to the cytokine levels. RESULTS: Serum concentrations of IL-1α, IL-1β, IL-4, IL-5, IL-10, IL-13, and IL-17 were significantly higher in AMD patients than in controls. None of the co-variables expressed a significant effect on the tested cytokines. Only IL-1a and IL-17 showed a statistically significant difference between groups (improved, unchanged, deteriorated) as determined by one-way ANOVA. Patients with increased macular thickness during treatment showed significantly lower levels of IL-17 compared to improved cases and to unchanged cases (p = 0.004, 0.03 respectively, Dunnett's T3 post hoc multiple test). TNF-α was significantly higher in improved cases compared to deteriorated cases (p =0.03, Dunnett's T3 post hoc multiple test). IL-17 was a significant predictor for macular oedema using linear regression (β = -0.888, p <0.05). CONCLUSION: Elevation of IL-1α, IL-1β, IL-4, IL-5, IL-10, IL-13, and IL-17 in the serum of AMD patients supports the hypothesis of AMD as an inflammatory disease. Patients with high IL-17 and TNF-α serum levels were more likely to have a favourable course under VEGF therapy. These cytokines may be used as easy-to-obtain biomarkers.
PURPOSE: This study evaluates the potential of serum pro-inflammatory cytokines as AMD biomarkers. METHODS: Serum samples from 30 age-related macular degeneration (AMD) patients and 15 age-matched controls were examined for 16 inflammatory cytokines using multiplex ELISA. Patients were divided into three subgroups (improvement/no change/deterioration during anti-VEGF treatment) by OCT and funduscopy, and correlated to the cytokine levels. RESULTS: Serum concentrations of IL-1α, IL-1β, IL-4, IL-5, IL-10, IL-13, and IL-17 were significantly higher in AMDpatients than in controls. None of the co-variables expressed a significant effect on the tested cytokines. Only IL-1a and IL-17 showed a statistically significant difference between groups (improved, unchanged, deteriorated) as determined by one-way ANOVA. Patients with increased macular thickness during treatment showed significantly lower levels of IL-17 compared to improved cases and to unchanged cases (p = 0.004, 0.03 respectively, Dunnett's T3 post hoc multiple test). TNF-α was significantly higher in improved cases compared to deteriorated cases (p =0.03, Dunnett's T3 post hoc multiple test). IL-17 was a significant predictor for macular oedema using linear regression (β = -0.888, p <0.05). CONCLUSION: Elevation of IL-1α, IL-1β, IL-4, IL-5, IL-10, IL-13, and IL-17 in the serum of AMDpatients supports the hypothesis of AMD as an inflammatory disease. Patients with high IL-17 and TNF-α serum levels were more likely to have a favourable course under VEGF therapy. These cytokines may be used as easy-to-obtain biomarkers.
Authors: Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge Journal: Ophthalmology Date: 2007-08-06 Impact factor: 12.079
Authors: Kathy H C Wu; Ava Grace Tan; Elena Rochtchina; Emmanuel J Favaloro; Andrew Williams; Paul Mitchell; Jie Jin Wang Journal: Invest Ophthalmol Vis Sci Date: 2007-05 Impact factor: 4.799
Authors: D V Jovanovic; J A Di Battista; J Martel-Pelletier; F C Jolicoeur; Y He; M Zhang; F Mineau; J P Pelletier Journal: J Immunol Date: 1998-04-01 Impact factor: 5.422
Authors: Julie L Gasperini; Amani A Fawzi; Ani Khondkaryan; Linda Lam; Lawrence P Chong; Dean Eliott; Alexander C Walsh; John Hwang; SriniVas R Sadda Journal: Br J Ophthalmol Date: 2011-07-26 Impact factor: 4.638
Authors: Fong Ming Mo; Alan D Proia; Walter H Johnson; Desiree Cyr; Kameran Lashkari Journal: Invest Ophthalmol Vis Sci Date: 2010-03-10 Impact factor: 4.799
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Sobha Sivaprasad; Temi Adewoyin; Tracey A Bailey; Sam S Dandekar; Sharon Jenkins; Andrew R Webster; Ngaihang Victor Chong Journal: Arch Ophthalmol Date: 2007-04
Authors: Julian Zimmermann; Marius Krauthausen; Markus J Hofer; Michael T Heneka; Iain L Campbell; Marcus Müller Journal: PLoS One Date: 2013-02-27 Impact factor: 3.240
Authors: Jacob K Sterling; Bailey Baumann; Sierra Foshe; Andrew Voigt; Samyuktha Guttha; Ahab Alnemri; Sam J McCright; Mingyao Li; Randy J Zauhar; Sandra R Montezuma; Rebecca J Kapphahn; Venkata R M Chavali; David A Hill; Deborah A Ferrington; Dwight Stambolian; Robert F Mullins; David Merrick; Joshua L Dunaief Journal: Cell Rep Date: 2022-06-14 Impact factor: 9.995
Authors: Douglas A Jabs; Mark L Van Natta; Michael F Schneider; Jeong Won Pak; Garrett Trang; Norman G Jones; Jeffrey Milush; Peter W Hunt Journal: AIDS Date: 2022-02-01 Impact factor: 4.632
Authors: Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez Journal: Methods Mol Biol Date: 2021
Authors: Maria Hytti; Eveliina Korhonen; Heidi Hongisto; Kai Kaarniranta; Heli Skottman; Anu Kauppinen Journal: Int J Mol Sci Date: 2021-06-24 Impact factor: 5.923